Psoriatic arthritis

Related records

Broader conditions (18)

• Arthritic joint disease
• Arthropathy
• Autoimmune disease
• Autoimmune disorder of musculoskeletal system
• Bone disorder
• Bone inflammation disease
• Connective tissue disorder
• Disease
• Disease by body system or component
• Disease by developmental or physiological process
• Human disease
• Immune system disorder
• Inflammatory disease
• Musculoskeletal system disorder
• Rheumatic disorder
• Rheumatoid arthritis
• Skeletal system disorder
• Syndromic disease

Narrower conditions (1)

• Psoriasis-related juvenile idiopathic arthritis

Trials (585)

• 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis
• 2 Years Prospective Study to Collect Real-life Data on the Retention, Quality of Life, Effectiveness and Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis
• 24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis
• 99mTc-anti-TNF-alpha Scintigraphy in the Evaluation of Inflammatory Processes Activity
• 99mTc-rhAnnexin V-128 in Diagnosis of Spondyloarthritis
• A 24 Week Open Label Study of the Utility of Adalimumab in Active Axial Forms of Psoriatic Arthritis
• A Belgian Registry of HUMIRA® (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis ( ProAct )
• A Canadian Open-Label Study to Evaluate the Safety and Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriatic Arthritis (PsA) (ACCLAIM)
• A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis
• A Clinical Study With Adalimumab Biosimilar
• A Clinical Trial of Antiplatelets in Psoriasis
• A Clinical Trial of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis
• A Controlled Trial of Intermittent Fludarabine for Psoriatic Arthritis
• A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis
• A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
• A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
• A Long-term Extension Study of Ustekinumab in Pediatric Participants
• A Multi-center RCT Clinical Trial on Personalized Precision Medicine for Patients With Psoriasis and Psoriatic Arthritis and Investigation on Cardiovascular Biomarkers
• A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta
• A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers

Approved drugs (23)

• Abatacept
• Adalimumab
• Apremilast
• Certolizumab pegol
• Cortisone acetate
• Dexamethasone
• Dexamethasone sodium phosphate
• Etanercept
• Golimumab
• Guselkumab
• Hydrocortisone
• Infliximab
• Isopropyl alcohol
• Ixekizumab
• Leflunomide
• Methotrexate
• Methylprednisolone
• Prednisolone
• Prednisone
• Risankizumab

Drugs in development (36)

• Alefacept Phase 2
• Belumosudil Phase 1
• Bimekizumab Phase 3
• Brepocitinib Phase 2
• Brodalumab Phase 3
• Cannabidiol Phase 2
• Cannabinol Phase 2
• Clazakizumab Phase 2
• Deucravacitinib Phase 3
• Dimethyl fumarate Phase 2
• Dronabinol Phase 2
• Efalizumab Phase 1
• FAPI GA-68 Early phase 1
• Filgotinib Phase 3
• Fludarabine Phase 2
• Gamcemetinib Phase 1
• GSK-3050002 Phase 1
• HOKT3 Phase 2
• Icotrokinra Phase 3
• Ivarmacitinib sulfate Phase 3

Other linked drugs (2)

• Metformin
• Picankibart